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Abstract
Next generation sequencing technology is advancing genome sequencing at an unprecedented level. By unravelling the
code within a pathogen’s genome, every possible protein (prior to post-translational modifications) can theoretically be
discovered, irrespective of life cycle stages and environmental stimuli. Now more than ever there is a great need for high-
throughput ab initio gene finding. Ab initio gene finders use statistical models to predict genes and their exon-intron
structures from the genome sequence alone. This paper evaluates whether existing ab initio gene finders can effectively
predict genes to deduce proteins that have presently missed capture by laboratory techniques. An aim here is to identify
possible patterns of prediction inaccuracies for gene finders as a whole irrespective of the target pathogen. All currently
available ab initio gene finders are considered in the evaluation but only four fulfil high-throughput capability: AUGUSTUS,
GeneMark_hmm, GlimmerHMM, and SNAP. These gene finders require training data specific to a target pathogen and
consequently the evaluation results are inextricably linked to the availability and quality of the data. The pathogen,
Toxoplasma gondii, is used to illustrate the evaluation methods. The results support current opinion that predicted exons by
ab initio gene finders are inaccurate in the absence of experimental evidence. However, the results reveal some patterns of
inaccuracy that are common to all gene finders and these inaccuracies may provide a focus area for future gene finder
developers.
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Introduction
Discovering novel proteins that are potentially expressed by a
pathogen in a host is still a major challenge facing the scientific
community. The laboratory approach for discovering proteins is
hindered by restrictions and limitations, such as: some pathogens
are difficult and/or dangerous to cultivate in the laboratory; the
expression of proteins may be different in vitro than those proteins
expressed during infection in vivo; the expression of proteins may
be different at various stages of the life cycle of the pathogen or
under altered environmental conditions; and there is a bias
towards abundant proteins that are more easily identified in the
laboratory [1].
Discovering proteins is further challenged by the fact the
literature now conclusively shows that a single gene produces
multiple protein isoforms under varying conditions, which
drastically increases the scale and scope of the proteins to discover
[2]. Experimentally creating all the relevant conditions to capture
the entire complement of proteins is beyond current technology.
Currently, the laboratory approach can only capture a subset of an
unknown sized proteome. It is expected that many important
proteins are eluding the capture and consequently are absent from
further downstream analysis. Even RNA-seq – a revolutionary tool
for transcriptome analysis [3], which undoubtedly will discover
novel proteins and protein isoforms – is still faced with the same
laboratory restrictions and limitations in capturing mRNA.
An in silico approach has the potential to capture the proteins
missed during the laboratory discovery process. It is well-known
that the nuclear genome of a pathogen encodes the entire
repertoire of genes, which potentially can express as proteins.
Theoretically, therefore, every possible protein (prior to post-
translational modifications) can potentially be discovered, irre-
spective of life cycle stages and environmental stimuli, by
unravelling the code within the genome. The falling cost and
on-going improvements in next generation sequencing technology
is advancing sequencing of genomes at an unprecedented level. It
is not inconceivable to expect that in the very near future we will
readily have available a genome sequence for any strain that has
been isolated and have multiple genome sequences of the same
strain. Now more than ever there is a great need for high-
throughput ab initio gene finding in order to mine this data for
genes.
Research into identifying genes in anonymous genomic
sequences has been going on for more than 20 years and there
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is an abundance of literature [4,5,6,7,8,9,10]. Gene finding has
proved to be an immense challenge [11]. On one hand there is
practically a universal pattern to the exon-intron structure of
eukaryotic genes but on the other hand the pattern creates much
ambiguity. Most eukaryotic genes begin with a start codon of ATG
and end with one of three possible stop codons – TAG, TAA, or
TGA. Non-ATG start codons do exist and are discussed in the
literature [12,13,14], but they are comparatively rare in eukary-
otes. There are no known non-standard stop codons in eukaryotic
genomes although, as a rare exception, the relatively uncommon
amino acid selenocysteine is encoded by the stop codon TGA [15].
Embedded between the start and stop codons are zero or more
introns (non-coding regions), which are delimited by donor sites
(typically GT) and acceptor sites (typically AG) [16]. There are a
few cases of splice sites in the literature [17,18] that deviate from
the typical GT-AG. The ambiguity occurs because not all ATGs
in a DNA sequence code for a start codon, and not all GTs and
AGs are splice sites. Thus, unlike the actual spliceosome of a
eukaryotic cell, no algorithm as yet can precisely recognise exon-
intron structures from DNA sequence alone. The best achievable
approach from an ab initio perspective is to use statistical models to
predict genes and their exon-intron structures. There are numerous
gene prediction programs freely available which attempt to meet
the challenge. At the time of writing, more than 60 could be found
in the literature though many of the published URLs were no
longer valid. Table 1 shows a small sample of the most common
gene finders. The disparity in their gene predictions for the same
DNA sequence shows that the gene finding challenge is still to be
overcome [10].
The representation of all eukaryotic pathogens at the genetic
level is structured the same i.e. a series of four nucleotides with
motif signals (start and stop codon, and donor and acceptor sites)
defining the coding exons. Since most of the popular ab initio gene
finders work within this universal gene structure and take into
account the pathogen’s compositional (codon) biases, it is not the
type of pathogen that mostly affects the accuracy of the
predictions. Irrespective of the pathogen, gene finders can have
a better or worse accuracy depending on the quality of input and
training data [41]. For example, a gene finder always performs
better when using a model trained on a target rather than a foreign
pathogen [9].
In addition to ab initio (or intrinsic) [6], there are two other
methods to computational gene finding – evidence based (or
extrinsic) [42], and genome sequence comparison [31]. Strictly
evidence based gene finders use evidence such as DNA copies of
mRNA (cDNA) and/or proteins and/or expressed sequence tags
(ESTs) [16]. They work by aligning evidence sequences, ideally
from different types, to the pathogen genome based on sequence
similarity. In effect the evidence constitutes combined exons and
the alignment to genome attempts to reintroduce introns into the
evidence to determine the exon-intron structure of the gene.
Evidence based gene finders are ideal for genomic annotation but
have limited value for finding novel genes. Aligning an mRNA or a
protein sequence (which has been translated back to nucleotides)
to a genome provides no additional evidence that it is a novel
protein (this is not surprising since they are in themselves the
evidence for a potential novel protein irrespective of any
alignment). Programs such as BLASTP (if given protein evidence)
and BLASTX (if given mRNA evidence) to find homologs would
be more appropriate than a gene finder to determine if an mRNA
or protein is novel. Genome sequence comparison exploits the use
of sequence conservation to help in identify coding exons. The
underlying principle of the method is to compare anonymous
genomic sequences from the same or different organisms, under
the assumption that regions conserved in high complexity
sequences will tend to correspond to coding exons from
homologous genes [43]. In other words, the conserved regions
between related organisms are more likely to be coding, and
conversely the divergent regions more likely to be non-coding.
Genome sequence comparison has the potential to discover novel
genes and is becoming a more feasible method owing to the
increasing availability of genome sequences [44].
This paper explores whether existing bioinformatics tools can
efficiently discover pathogen proteins missed by laboratory
techniques and in effect describes an evaluation of publicly
available gene finders when used in the absence of experimental
evidence. Toxoplasma gondii, which is an apicomplexan pathogen
responsible for birth defects in humans [45], was the chosen
species to illustrate the evaluation methods and to compare the
performance of the gene finders. This pathogen was particularly
chosen because it is an important model system for the phylum
Table 1. Gene finders in chronological order based on release
year.
Year Gene Finder Name Type++ Comments
1991 GRAIL [19] Ab initio No longer
supported
1992 GeneID [20] Ab initio
1993 GeneParser [21] Ab initio
1994 Fgeneh [22] Ab initio Finds single exon
only
1996 Genie [23] Hybrid
1996 PROCRUSTES [24] Evidence based
1997 Fgenes [25] Hybrid No download
version
1997 GeneFinder Ab initio Unpublished work
1997 GenScan [26] Ab initio
1997 HMMGene [27] Ab initio No download
version
1997 GeneWise [28] Evidence based
1998 GeneMark.hmm [29] Ab initio
2000 GenomeScan [30] Comparative
2001 Twinscan [31] Comparative
2002 GAZE [32] Comparative
2004 Ensembl [33] Evidence based
2004 GeneZilla/TIGRSCAN [34] Ab initio No longer
supported
2004 GlmmerHMM [34] Ab initio
2004 SNAP [9] Ab initio
2006 AUGUSTUS+ [35] Hybrid
2006 N-SCAN [36] Comparative
2006 Twinscan_EST [37] Comparative+
Evidence
2006 N_Scan_EST [37] Comparative+
Evidence
2007 Conrad [38] Ab initio
2007 Contrast [39] Ab initio
2009 mGene [40] Ab initio No longer
supported
++Hybrid = ab inito and evidence based; Comparative = genome sequence
comparison.
doi:10.1371/journal.pone.0050609.t001
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Apicomplexa [46,47,48] and has experimentally validated data
that can be used for training and testing. All apicomplexans
differentiate to forms that invade single or multiple hosts to
complete extremely complex life cycles. For example, Toxoplasma
gondii can infect almost any tissue of warm blooded animals [49]
and possesses several life cycle stages yet to be completely
characterised at the proteome and transcriptome level. Experi-
mentally creating all the relevant conditions, from which to
capture the entire complement of expressed proteins, is beyond
current technology. Consequently, there are novel proteins
encoded in apicomplexan genomes that have presently missed
capture by laboratory techniques, which theoretically could be
captured by ab initio gene finders. An important aim here is to
identify possible patterns of inaccuracies that are common to all
evaluated gene finders irrespective of the pathogen, such as: are
the start and/or stop exons predicted less accurately than internal
exons? Does the distance between exons affect accuracy? Is there
any difference in accuracy between forward and reverse strand
predictions? Knowing common inaccuracies may provide a focus
area for future gene finder developers.
Methods
There were seven specific tasks undertaken to complete the
overall evaluation of the gene finders: 1) selecting the appropriate
gene finders for evaluation, 2) collating a validated dataset and
creating training models specific to each gene finder, 3) evaluating
the prediction accuracies using sensitivity and specificity measures,
4) determining how well the gene finders perform in locating genes
by aligning predicted and test sequences, 5) evaluating at the
protein level, 6) classifying the predicted gene locations relative to
test genes, and 7) finding potential novel genes.
Selecting the Gene Finders for Evaluation
The initial challenge was determining which gene finder
programs, from so many, to include in the evaluation. To narrow
down the number of candidates, there were six important criteria
used to assess the inclusion or exclusion of a program – public
availability, operating platform, high-throughput functionality, cell
type, training data, and software support. Each criterion is now
described in more detail: 1) Public availability – the program had
to be freely downloadable and have standalone capability; 2) Type
of operating platform – the numerous programs potentially
available can be classified into three platform categories: web
interface, Microsoft Windows, and Linux. The web interface
programs are by far the most prevalent due to their immediate
accessibility (i.e. no installation) and ease of use. However,
processing enormous amounts of input to find genes on a genome
wide scale is currently unproductive through web interfaces. Only
Linux supported programs were chosen because Linux is
becoming an international standard for academia and research;
3) High- throughput functionality – the programs needed to
process large numbers of input in a timely manner. What
constitutes processing completion in a ‘timely manner’ is
debatable. Most of the standalone programs trialled gave no
indication of progress when executed. Here, if the command
prompt was not returned within 48 hours it was assumed the
program was in a loop (hanging) and subsequently excluded from
the selection process; 4) Cell type – only programs specific to
eukaryotic organisms were used; 5) Training data – the program
had to either provide a readymade trained model or functionality
to create one for the target pathogen; and 6) Maintained and
supported – ideally the program should have documentation,
contact support for bug fixes and enhancements, and most
importantly work consistently without errors. This criterion was
only partly fulfilled for most programs. So in summary the
programs chosen for evaluation were standalone programs for
eukaryotes that could be freely downloaded, executed in a Linux
environment, enable high-throughput processing, and have either
a readymade trained model or functionality to create one for the
target pathogen.
Four ab initio gene finder programs fulfilled the selection
criteria–GeneMark.hmm [29], AUGUSTUS [35,50], SNAP [9],
and GlimmerHMM [34,51]. The programs GeneZilla [34],
mGene [40] (uses machine learning techniques), and Conrad
[38] (based on conditional random fields) were tested but not
included for evaluation due to consistent undocumented program
crashes. All the evaluated gene finders use a variation of hidden
Markov models (HMMs) [52]. A HMM is used to statistically
model structure of DNA sequences and each gene finder has its
own complex internal algorithm to decode the HMM into gene
predictions [16]. The Supporting Information S1 provides detailed
information about these gene finders including download URLs,
and basic background on gene prediction and HMMs. For specific
details on how these programs work refer to the following
references [9,29,34,35]. All evaluated gene finders run in a
command-line mode and to effectively run them it was required to
know for each program the format of the input files, the
command-line parameters (as they vastly impact the output), and
the type of output to expect. For brevity, the commands and
parameters used for setting up and running the programs are also
in Supporting Information S1.
Creating Training and Validated Datasets
The fundamental method for evaluating gene finders is
comparing predicted genes with validated genes at the nucleotide,
exon, and gene level [8]. Finding experimentally validated genes
and extracting the exons is not a straightforward task. The method
used to obtain gene sequences and their exon locations for the
evaluation is described in Supporting Information S1. A validated
gene set was created which comprised all genes from the T. gondii
genome that have evidence for protein expression based on mass
spectrometry analyses. These genes (3,432 in total) were down-
loaded from ToxoDB database [53]. The ToxoDB database is a
central depository specific to various types of T. gondii biological
data and can be found at http://toxodb.org/toxo/. All down-
loaded genes were checked to confirm expected start codon
(ATG), stop codon (TAG, TGA, or TAA), donor (GT) and
acceptor (AG) consensus sequences. Any genes not meeting this
expectation were removed from the validation set. There were five
exceptions for the start and stop codons, no exceptions for
acceptor sequences, and 129 for donor sequences. However, these
129 genes uniformly had GC as the donor sequence and were not
removed on the assumption that this alternative donor consensus
(as in non-canonical splice site) was not a manifestation due to
sequencing errors. A check to see if there were any redundant
genes was also conducted. If two genes from the same
chromosome had a 95% or greater similar coverage the gene
with the smallest query length was removed from the validated set.
No redundant genes were found. Several genes had 100%
coverage to genes from a different chromosome. These genes
were not removed.
All four evaluated gene finders required a training dataset. The
creators of the programs SNAP, AUGUSTUS, and Glim-
merHMM provide training programs that require specific input
data to train hidden Markov models. The input data consists of
two files: one file containing the DNA sequences of experimentally
validated genes in a multi-FASTA format, and the other
Ab Initio Gene Finders for Eukaryotic Pathogens
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containing start and end exon base pair locations of these gene
sequences. The format of the exon file is non-standard and is
specific to each program. The exon locations are relative to the
start of the gene sequence. Figure 1 shows an example format of
an exon file before amendments. The gene sequence starts at
position 1 and the start exon (ATG codon) starts at position 1 on
the sequence and ends at 4038. As will be shown in the results, the
accuracy of gene finders is governed not only by the number of
validated genes in the training dataset but also by the number of
nucleotide bases preceding and trailing the coding segment (CDS)
sequence. Figure 2 shows an example of these flanking nucleotide
bases. The exon location file must reflect the extended CDS
sequences due to the flanking bases. For example, if the extension
is 500 bases before and after the CDS the first exon in Figure 1
would start at 500 and end at 4538.
In-house Perl scripts were used to create the required input files
for the training programs. The evaluation was performed on a
chromosome per chromosome basis. A defined number of gene
sequences were randomly extracted from the validation set but any
target chromosome genes and genes used for testing were
excluded. In addition, extracted gene sequences included a
defined number of flanking bases before and after the CDS. For
the evaluation the following were extracted: three sets containing
250, 500, and 1000 training genes with 250, 500, and 1000
flanking bases. In effect there were nine files containing training
genes, e.g. one file contained 250 genes sequences with 250
flanking bases; another contained 250 genes with 500 flanking
bases, and so on. There were also nine associated files per gene
finder containing the base pair locations of the exons within these
training gene sequences. For example, one of the nine files
contained exon locations for 250 training genes and the locations
were modified by 250 to account for the flanking nucleotides in the
training gene. Each of the nine training gene files along with their
associated exon location files were input one at a time into the
gene finder-specific training program to create nine separate
model parameters. The model parameters are essentially proba-
bility distributions used by gene finders.
Evaluating the Accuracy of Gene Finders Using the
Measures of Sensitivity and Specificity
There are only four possible prediction outcomes – true
positive, false positive, true negative, and false negative. Most
gene finder evaluations found in the literature [8,16,35,54,55]
report the accuracy of predictions using the conventional measures




These measures were also adopted here, however, there appears
to be no clear convention in the literature on how the outcome
classifications should be made at each level, and in particular the
exon and gene level. What follows is how the classifications were
determined for the evaluation presented here. Firstly, the
evaluation was performed on only one T. gondii chromosome.
The test genes used to compare the accuracy of the predictions for
the target chromosome were extracted from the validation set.
These test genes represent a subset of an unknown number of
genes encoded in the target chromosome. Consequently, if the
predictions were evaluated with respect to the entire chromosome,
only a true positive or false negative outcome could be stated with
any level of certainty. For example, the outcome for a particular
prediction would be classified a false positive if there is no known
gene within the predicted region of the chromosome. It is possible,
however, that this region could in fact encode a gene yet to be
discovered experimentally. Therefore, the evaluation presented
here was only performed within the CDS region of the test gene.
Evaluation at the nucleotide level involved classifying each
nucleotide within the CDS as coding (i.e. nucleotide located on
an exon) or non-coding (i.e. nucleotide located on an intron).
Figure 3 shows an example of prediction outcomes at the
nucleotide level. A true positive outcome was when a predicted
coding nucleotide exactly aligned with a coding nucleotide on the
test gene, a false positive was when a predicted coding nucleotide
aligned with a non-coding nucleotide on the test gene; and a false
negative was when a predicted non-coding nucleotide aligned with
a coding nucleotide. For the classification at the exon level, the
exact alignment of an entire exon was a positive outcome and all
other predicted exons were false positive outcomes. A false
negative was when an exon in the test gene was not predicted or
incorrectly predicted. Figure 4 shows an example of prediction
outcomes at the exon level. For a true positive outcome at the gene
level, every exon in the CDS of the predicted gene must precisely
align to the respective exon in the CDS of the test gene. This is a
stringent test since only one incorrect exon ensures a false positive
outcome. A false negative was when a gene in the test set was not
predicted or one exon incorrectly predicted. In preliminary testing
of the gene finders it was shown that given the same DNA
sequence, input parameters, and training data they make the same
prediction each time. The gene finders in the evaluation were only
executed once per test training model.
Evaluation of Gene Finders by Aligning Predicted and
Test Sequences
Predicted gene sequences derived from the nine training set files
were also aligned to the test gene sequences using BLASTN. In a
similar way, gene finder programs that use genome sequence
comparison, such as N-SCAN [36] (a descendant from TWIN-
SCAN 2.0, which is in turn a descendant of GenScan [26]), first
perform ab initio gene predictions and then compare the
predictions against a collection of sequences from an informant
genome using BLASTN.
BLASTN is part of the BLAST suite of applications. Predicted
genes that aligned with an expect value equal to 0 and with 100%
coverage were of particular interest because it is an indication of
how well the gene finders perform in locating the gene in a DNA
sequence. The expect value, often referred to as an e-value, is a
parameter that describes the number of ‘‘hits’’ (i.e. matches)
expected due to chance when searching a database of a particular
size – the lower the e-value the more ‘‘significant’’ the match.
Figure 1. Example of exon location file. The first column is the
feature name. The second and third column defines that start and end
location of the exon relative to the ‘‘Einit’’ feature. The last column is the
name of the gene sequence relative to the exon locations.
doi:10.1371/journal.pone.0050609.g001
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Evaluation of Gene Finders at the Protein Level
Whilst the evaluation of gene finders at the nucleotide, exon,
and gene level is appropriate, evaluation at the predicted protein
level is considered equally important. To reiterate, a desired goal
from ab initio gene finders is to use the output to discover novel
proteins. Incorrect predicted exons manifests in incorrect transla-
tions to amino acid residues. The question is whether the
translated DNA sequence is sufficiently accurate to be used as a
query to find existing proteins (homologues). The output
predictions from the gene finders are in the form of exon genomic
coordinates. In-house Perl scripts were used first to obtain
nucleotide sequences based on the predicted exon locations from
each gene finder, and then to translate into protein sequences in
FASTA format. A stand-alone BLASTP was used to search a
protein database using the predicted protein sequences as queries
(BLASTP is also part of the BLAST suite of applications). The
protein database is called ‘‘nr’’ and was downloaded from NCBI
FTP site. The comprehensive nr database contains all non-
redundant GenBank coding segment (CDS) translations, NCBI
RefSeq proteins, proteins from Protein Database (PDB), UniProt,
International Protein Sequence Database (PIR), and Protein
Research Foundation (PRF). BLASTP aligns the amino acid
residues of the predicted sequence with each nr database sequence
in turn to achieve maximal levels of identity and conservation (in
the case of amino acid sequences) for the purpose of assessing the
degree of similarity and the possibility of homology (modified from
http://www.ncbi.nlm.nih.gov/books/NBK62051/). Every align-
ment in which the e-value is lower than a threshold parameter is
reported as a hit. In the evaluation all default BLASTP parameters
were adopted and output restricted to include only: query ID,
query sequence length, subject ID (e.g. ID in nr database),
alignment length (same as subject sequence length), identity, and
expect value. An in-house Perl script was used to parse the
BLASTP output and to evaluate the consistency among the gene
finders. For example, if all four gene finders significantly matched
(i.e. a hit with an e-value equal to 0) with the same protein then the
prediction was considered more trustworthy than a prediction
made by only one gene finder. Other studies [54,56,57] have used
BLASTP to evaluate predictions.
Classifying the Predicted Gene Locations Relative to the
Test Genes
An in-house Perl script was used to evaluate the accuracy of
gene finders in identifying the location of a gene within a
chromosome. An incorrect start and end location of a gene
manifests into an incorrect exon-intron structure. The script
compared the gene locations, derived from the best predictions
from each gene finder, with the start and end genomic location of
the test genes. A predicted gene location can have one of seven
possible locations relative to a test gene: 1) start and end location
exactly the same; 2) start and end entirely within test gene; 3) start
and end extend beyond test gene (i.e. test gene entirely within
predicted gene); 4) start but not the end is the same; 5) end but not
the start is the same; 6) end overlaps the start of test gene; and 7)
start overlaps the end of the test gene. Figure 5 shows the seven
classifications. Each prediction was assigned to one of the seven
classifications. These classifications were used as an aid to
determine how well the gene finder identified the location of
genes. Another study [56] clusters predictions by genomic
locations.
Similarly, a comparison of the genomic start and end locations
of exon predictions with exons in the test genes was performed
with an in-house Perl script. The approach used to classify the
exons is similar to another study [58], except we used seven exon
classifications as per Figure 5 rather than thirteen. The general
aim of the approach was to identify common patterns of
Figure 2. Example of flanking nucleotide bases appended to coding segment. It is required that a set number of nucleotide bases are
added before and after the coding segment (CDS) sequence when assembling training genes.
doi:10.1371/journal.pone.0050609.g002
Figure 3. Schematic representation of gene prediction evaluation at the nucleotide level. Abbreviations: C = coding nucleotide located
on exon, N =non-coding nucleotide located on intron, TP = true positive, FP = false positive, TN= true negative, and FN= false negative.
doi:10.1371/journal.pone.0050609.g003
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incorrectly predicted exons relative to the boundaries (i.e. the start
and end of exons) of the test exons.
Finding Novel Genes
Due to the inaccuracies of individual gene finders in general, it
has been proposed several times in the literature [10,55,59] that
the most judicious approach to finding genes is to combine the
predictions from a pool of gene finders. There are programs such
as EvidenceModeler [60], JIGSAW [61], Evigan [62], and
GLEAN (http://sourceforge.net/projects/glean-gene) that com-
bine ab initio gene predictions and other evidence (e.g. protein and
transcript alignments) into consensus gene predictions. In this
study, which is specifically to evaluate ab initio gene finders, the
assumption is that there is no other evidence. To find potential
novel genes (and ultimately novel proteins), the predicted DNA
sequences from each gene finder were grouped according to
similar start and end locations on the chromosome. For example, a
group would contain all predicted sequences where either the start,
or end, or both start and end locations of the sequences
overlapped. The sequences in each group were then aligned
relative to their genomic start locations. A consensus sequence was
derived for each aligned group. Some predicted sequences that
overlap during the grouping process can cause the consensus
sequence to potentially contain more than one gene i.e. there can
be multiple breaks in the consensus. For example, the aligned
group may contain a length of consensus sequences followed by a
stretch of sequences where no consensus can be found, and then
another length of consensus sequences. Therefore, any group
consensus sequence containing a break was split at the break into
individual consensus sequences. It is possible, however, this action
can erroneously split a group consensus that correctly represents
one gene but contains a break due to poor prediction. All
consensus sequences were assumed to represent one gene and were
checked to ensure that they start with an ‘‘ATG’’ and end with
either ‘‘TAG’’, ‘‘TAA’’, or ‘‘TGA’’. The consensus sequences
fulfilling this start and end requirement were used as a query to
BLASTX. BLASTX is also part of the BLAST suite of
applications. The BLASTX algorithm was used to compare the
six-frame conceptual translation products of the consensus
sequences against the protein sequences in the nr protein database.
The expectation was that the regions in the consensus sequence,
which represent exons, would align to known protein sequences.
This expectation was based on the fact that the top BLASTX ‘‘hit’’
for all test genes was to relevant T. gondii proteins. A consensus
sequence that did not align to a Toxoplasma protein was deemed a
potential novel gene worthy of further investigation.
Results
The data from the pathogen T. gondii was used to evaluate the
efficacy of the ab initio gene finders. The purpose of the evaluation
was to determine the effectiveness of ab initio gene finders as a
whole in the discovery of novel proteins missed by laboratory
techniques rather than to publish that one gene finder is
necessarily better than another. The focus here is also on the
performance of the gene finders and in particular possible patterns
of prediction inaccuracies. No attempt is made to propose
scientific findings for T. gondii as it is beyond the scope of the
paper.
The T. gondii genome is approximately 63Mb in size and
consists of 14 chromosomes. Gene predictions were performed on
T. gondii (ME49 strain) chromosome VIIb downloaded from
ToxoDB database at http://toxodb.org/toxo/. The length of the
chromosome is 5,023,922 base pairs and reportedly contains 678
Figure 4. Schematic representation of gene prediction evalu-
ation at the exon level. Exons are represented by shaded rectangles.
Introns are represented by the adjoining solid lines. Abbreviations:
TP = true positive, FP = false positive, and FN= false negative.
doi:10.1371/journal.pone.0050609.g004
Figure 5. The seven classifications of the predicted gene locations relative to a test gene.
doi:10.1371/journal.pone.0050609.g005
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genes as per the number of entries in ToxoDB. Of the 678 gene
entries, 377 are hypothetical proteins (i.e. no known homologs).
Sensitivity and Specificity of Gene Finders
Table 2 shows the evaluation of three of the gene finders
(GlimmerHMM, SNAP and AUGUSTUS) at gene, exon, and
nucleotide level. GeneMark_hmm was excluded from the sensi-
tivity and specificity measures because it provides no facility to
create user-defined training models. GeneMark_hmm provides
instead a readymade training set for T. gondii. The test genes, and
therefore genes on the target chromosome VIIb, were excluded
from the training genes in this evaluation stage. There were three
main points inferred from this evaluation test. The first point was
that the gene finders have extremely low accuracy in precisely
determining the exon-intron structure of gene. For example, the
highest exon sensitivity (SN) and specificity (SP) was for
AUGUSTUS with 0.52 and 0.56 respectively, followed by 0.47
and 0.37 for SNAP, and then the least accurate 0.27 and 0.31 for
GlimmerHMM. The second point is that the accuracy of gene
predictions improves as the number of training genes increases.
This result is as expected, however, an inherent bias when using
training datasets is that algorithms will find genes most similar to
those in the training data [41]. Determining the optimal number
of training genes is a challenge. Table 3, for example, clearly
shows that using all validated genes (3,432 including the test genes)
in the training model gives the best results. It is impossible
nevertheless to ascertain whether only genes similar to training
genes are found because the complete number of true genes on the
chromosome is unknown, i.e. it is not possible to check for
overtraining. Therefore, we propose that it is currently an art to
achieve an optimal balance between accuracy and overtraining. In
addition to the number of genes in the training set the prediction
accuracy also depends on the variety of genes in the training set. A
training set in effect represents an ‘‘average gene’’ so it can be
expected that some genes in the genome will not be predicted or
will be incorrectly predicted because they greatly differ in structure
or compositional biases to the so-called average gene [34]. The
third point inferred from Table 2, and supported by Table 4, is
that the number of nucleotides before and after the CDS impacts
accuracy but in a different manner for each gene finder. For
example, GlimmerHMM tends to be more accurate with more
flanking nucleotides, whereas SNAP tends to be the opposite. The
utilisation of these intricacies of different flanking requirements for
each gene finder is recommended in the deployment stage of the
gene finder. Table 3 also shows that using a HMM model trained
on humans substantially reduces the prediction accuracy and these
results further highlight the need to use only models trained for the
target organism.
On closer examination of Table 2 and Table 3 the specificity of
SNAP is significantly lower than sensitivity. This is because the
specificity calculation is distorted by partial predictions. For
example, the predictions made by SNAP align to only a part of the
test gene such that there tends to be more than one prediction per
test gene and some predictions overlap. The accuracy shown in
Table 3 for GeneMark_hmm is clearly much lower than the other
gene finders. Surprisingly the self-training version of GeneMark,
called GeneMark_hmm ES [63], is more accurate. However, the
history and the content of the T. gondii trained model used in the
evaluation of the supervised GeneMark_hmm are unknown and
hence it would be naive, and unfair to the creators, to conclude
that GeneMark_hmm is the least accurate gene finder.
How Well Predicted Sequences Align to Test Sequences
Table 4 shows the results from aligning the predicted gene
sequences with the test gene sequences (299 in total) using
BLASTN. As expected, the results supported the findings in
Table 2 and Table 3 i.e. there is an increase in the number of
matches with more genes in the training set. The number of
predicted genes also increases as the number of training genes
increases. For example, GlimmerHMM made 594 predictions
with 250 training genes and 659 predictions with 1000 training
genes. The increase in the number of predictions (65 in this case) is
most likely because of the increase in variety of structure and
compositional biases brought about by the increase in training
genes. In other words, the additional predictions did not conform
to the ‘‘average gene’’ of the 250 training set.
Despite the low accuracy of ab initio gene finders for precise
genomic annotation, the results in Table 4 are still encouraging
with respect to locating the genomic location of the gene within
the chromosome, even though the predicted exons may be
incorrect. GlimmerHMM, for instance, only precisely predicted
34 genes where all exon locations were correct out of a possible
299. The predicted nucleotide sequence, however, is of sufficient
accuracy to significantly align with 263 test genes.
The bottleneck to in silico discovery of proteins is the inaccurate
prediction of exon location within the DNA sequence i.e. the DNA
predictions translated to amino acids are imprecise since their
predicted exons are imprecise. Hence one prediction from one
gene finder is too uninformative to propose it is a novel protein.
However, if several gene finders all predict a similar gene region
within the genome then it is more likely that the genome encodes a
gene. The likelihood that it is a true novel gene increases when
other gene finder predictions in agreement can be matched to
experimentally validated genes.
Evaluation at Protein Level
Table 5 shows the results after translating the concatenated
DNA sequences of the predicted exons into amino acids and using
them as a query in BLASTP to find matching proteins in the
protein database (nr). As an example of interpretation, AUGUS-
TUS predicted 514 genes, of which 509 predictions (after
translation) significantly matched an existing protein and 5 did
not. Unmatched queries are most likely due to the inaccuracy of
predicted exons. It is nevertheless possible that some unmatched
queries are novel proteins.
A predicted protein sequence of a gene finder can match more
than one protein in the nr database. For example, in the case for
AUGUSTUS there were 1,194 significant (e-value = 0) protein
matches from 514 predicted protein sequences. There are two
possible reasons for this: 1) the same protein sequence has been
incorrectly added multiple times in nr under different IDs, or 2) it
is a different form of the same protein i.e. alternative splicing has
occurred.
If gene finders can successfully predict a certain percentage of
known proteins then we propose that it is reasonable to assume a
similar percentage of predictions with no homologous matches are
novel proteins. This assumption has more weight if all gene finders
predict a similar genomic location within the chromosome for the
same gene prediction. Table 6 shows the number of identical
predicted proteins found in the protein database (nr) per number
of gene finders. For example, 923 unique predicted proteins were
identified by all four gene finders. There were 1,603 unique
predicted proteins found in the protein database (nr) from a
combined number of 5,323 hits. Encouragingly the majority of
these unique proteins were found by all four gene finders and
consequently provide sound evidence that these translated DNA
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sequence are of sufficient accuracy to be used as queries to find
existing proteins (homologues). Proteins found by only one or two
gene finders are questionable predictions.
Prediction Statistics
Table 7 shows some statistics for the predicted and test genes.
The aim here was to identify similarities or differences between the
gene finders. For example, AUGUSTUS has the largest average
and longest distance between gene predictions. Predictions for all
gene finders are made throughout the chromosome and are evenly
distributed as shown by the predictions located in four chromo-
some partitions. AUGUSTUS also differs from the other gene
finders by making no predictions in the first 54,055 nucleotides (as
is the case for SNAP) and the last 21,392 nucleotides of the
chromosome. SNAP did not predict any single exon genes. In
contrast, GlimmerHMM predicted substantially more single exon
genes than any other gene finder.
A study [56] using three gene finders (GeneZilla [34], Twinscan
[31], and GlimmerHMM) to predict genes in T. gondii chromo-
somes showed that the length of the translated gene sequences for
GlimmerHMM (1,077 residues average length) were on average
much longer than GeneZilla (681 residues) and TwinScan (614
residues) translated predictions. No average genes lengths were
reported but the latter implies that GlimmerHMM predicts much
longer genes or predicts more exons or longer exons than the other
two gene finders. Our study suggests longer exons as Glim-
merHMM predicted gene sequences with an average length of
5,677 that was less than the predicted lengths of AUGUSTUS and
GeneMark_hmm but greater than SNAP. The average number of
exons per gene (5 exons) for GlimmerHMM was the smallest of all
the evaluated gene finders but the average length of the exons (448
nucleotides) was the largest.
Classification of Predicted Gene Locations Relative to the
Test Genes
Table 8 shows a comparison of the genomic start and end
locations of the gene predictions with the test genes. The start
location in this instance is the start of the initial codon (ATG) and
the end location is the end of the stop codon (TAG, TAA, or
TGA). AUGUSTUS clearly performed the best in locating the
start and end of genes precisely with 152 out of 299 but failed to
identify 26 of the test genes. AUGUSTUS was evaluated along
with GeneMark_hmm, GeneZilla, GeneID, and GenScan in the
human encode genome annotation assessment project (EGASP)
and was shown to consistently find the start and end of genes
better than the other evaluated ab initio gene finders [55].
Conversely GeneMark_hmm precisely identified only 31 but
identified (by partial overlapping) all 299 test genes. Gene-
Mark_hmm overlaps with more test genes because the average
length of its predicted genes is considerably greater than the
predicted genes of the other evaluated gene finders (see Table 7 for
statistics on predicted genes). GeneMark’s prediction length is too
long and this is supported by the fact that 116 predicted locations
are classified as ‘‘totally over’’ i.e. the test gene is located entirely
within the predicted gene. SNAP prediction lengths, on the other
hand, are too short since 90 are classified as ‘‘totally within’’ i.e.
the predicted gene is located entirely within the test gene. This
finding is also supported by the fact that 197 out of 895 predictions
constitute partial predictions and the average prediction length
(Table 7) is shorter than other gene finder average lengths. Partial
predictions are when only part of an entire gene is predicted such
that there can be more than one prediction to the same test gene
by the same gene finder. SNAP makes the most partial predictions
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All gene finders precisely locate the end of a gene slightly more
often than the start of a gene. This is expected due to the fact that
it is difficult to distinguish a functional start codon (ATG) from
other ATG triplets in the DNA sequence that code for the amino
acid methionine. Stop codons on the other hand normally do not
code for any amino acids. Table 8 also shows the location
classifications when using a consensus of the gene finder
predictions. For example, consensus sequences constructed from
all four gene finders precisely define the start and end of 89 test
genes. Different combinations of gene finders were tested to
achieve the optimal combination. The combination of AUGUS-
TUS and Glimmer marginally achieved the best result with 268
gene boundaries precisely identified (start and end = 127, start =
60, end = 81) and 273 test genes identified.
A question that arose was why the gene finders, and in
particular AUGUSTUS, failed to identify some of the test genes.
The test genes not found were compared to see if there was any
similarity or pattern to these genes. The results are shown in
Table 9. AUGUSTUS failed to identify 26 test genes of which
61.5% were genes from the reverse strand, 50% were single exon
genes, and the average length of the test genes not found was
67.5% less than the average length of all test genes. In addition,
70% of the single exon genes were from the reverse strand. The
two test genes not identified by GlimmerHMM were single exons
genes both from the reverse strand. SNAP failed to identify 16 test
genes of which 75% were from the reverse strand, 56% were single
exon genes, and the average length was 65.1% less than the
average length of all test genes. Table 10 shows the number of test
genes not found that are in common with the evaluated gene
finders. It is proposed from these findings that the gene finders, in
general, have greater difficulty in identifying single exon genes or
shorter than average length genes that are located on reverse
strands.
Table 11 shows the comparison of the genomic start and end
locations of exon predictions with exons in the test genes. The
values in the table are percentages of the number of exons falling
into one of the seven classifications. For exons that were classified,
there were more exons in classification one (start and end
boundary correct) than any other classification. More start
boundaries were correctly identified, which suggests that all gene
finders have a greater difficulty in predicting end boundaries of
exons. Many test exons were not overlapped in any way. For
example, 40% of the test exons were missed by GeneMark_hmm.
It is tempting to assume here that SNAP performed the best by
only missing 9% of the test exons, but some of SNAP’s exon
predictions are duplicates.
In a similar exon classification study [58], four ab initio gene
finders (AUGUSTUS, Genezilla [34], GlimmerHMM, and
SNAP) and two comparative genomics gene finders (GenomeScan
[30] and Twinscan [31]) were tested on human DNA. Each
evaluated gene finder was trained on a different dataset. With
reference to the exon classification in Figure 5 and Table 11, the
findings of the latter study were mostly in agreement with our
results: 1) the gene finders predicted more class 1 (start and end
boundary correct) than any other class (GeneMark and Glim-
merHMM are the exceptions in our study); 2) the second largest
class was for predicted exons that did not overlap the test exons in
any way; 3) the third largest class was for exons that correctly
matched either the start boundary (class 2) or end boundary (class
3) – in our study, there were more predictions that overlapped
either the start boundary (class 6) or end boundary (class 7) than
class 3; 4) no exons were predicted such that their end boundary
matched the test start boundary or their start boundary matched
the test end boundary; 5) the predicted start boundary of an initial
exon of a multi-exon gene tended to occur after the test start when
the predicted end boundary was correct i.e. the gene finders
tended to incorrectly predict shorter initial exons; 6) the predicted
end boundary of a terminal exon tended to occur after the test end
when the predicted start boundary was correct i.e. gene finders
were more likely to predict exons extending beyond the stop
codon; 7) no gene finder predicted a single exon gene that started
correctly and ended before the stop codon; and 8) incorrectly
predicted exons that did not overlap the test exon in any way,
occurred more often after the test exon than before.
Table 6. Identical proteins found in protein database per





923 4 AUGUSTUS, Glimmer, GeneMark, SNAP
257 3 AUGUSTUS, Glimmer, GeneMark
84 3 Glimmer, GeneMark, SNAP
25 3 AUGUSTUS, Glimmer, SNAP
8 3 AUGUSTUS, GeneMark, SNAP
57 2 Glimmer, GeneMark
43 2 AUGUSTUS, Glimmer
25 2 Glimmer, SNAP
14 2 AUGUSTUS, SNAP
8 2 AUGUSTUS, GeneMark





1603= Total number of unique proteins
doi:10.1371/journal.pone.0050609.t006
Table 5. Protein homology search on translated gene finder predictions.
Gene Finder Gene predictions Homology found$$ Homology not found
AUGUSTUS 514 509 5
GeneMark.hmm 580 481 99
SNAP 895 734 161
GlimmerHMM 710 657 53
$$Includes duplicate proteins. Duplicate proteins are when several gene predictions match to the same protein.
doi:10.1371/journal.pone.0050609.t005
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Table 7. Statistics for predicted and test genes.
Statistics for … AUGUSTUS GlimmerHMM SNAP GeneMark_hmm Test genes
Number of genes 514 710 895 580 299
Gene Length
Shortest 270 201 399 303 298
Longest 44325 37271 22713 45369 47133
Average 5733 5677 4679 7979 5388
Range 44055 37070 22314 45066 46835
Number of genes
containing an N
10 17 22 19 5
Distance between genes
Shortest 29 0 0 104 52
Longest 31658 8549 21815 4677 106560
Average 3894 1398 3112 664 11081
Range 31629 8549 21813 4573 106508
Percentage of overlaps 0 0.4 26.9 0 0
Chromosome gene region
Length of chromosome 5023922 5023922 5023922 5023922 5023922
Start of first gene 54055 635 54055 7447 78150
End of last gene 5002530 5020498 5023141 5020134 5002376
Range 4948475 5019863 4969086 5012687 4924226
Distance to start of
chromosome
54055 635 50455 7447 78150
Distance to end of
chromosome
21392 3424 781 3788 21546
Percentage of genes located in:$$
Partition 1 26.1 26.3 25.1 27.1 26.4
Partition 2 24.7 23.3 25.6 24.5 25.7
Partition 3 24.5 25.1 24.5 24.1 21.4
Partition 4 24.7 25.2 24.8 24.3 26.4
Exons
Total number 3357 3334 4746 4172 2013
Shortest exon 3 5 5 7 3
Longest exon 9981 9981 9977 9985 9981
Average length 403 448 364 380 350
Average number per gene 7 5 6 8 7
Highest number per gene 46 31 29 47 47
Lowest number per gene 1 1 2 1 1
Number of single exons 67 123 0 63 39
Introns
Total number 2844 2624 3851 3592 1714
Shortest intron 43 4 4 23 51
Longest intron 5834 5707 6734 9961 3560
Average length 560 968 640 848 530
Average number per gene 6 4 5 7 6
Highest number per gene 45 30 28 46 46
Lowest number per gene 1 1 1 1 1
$$The target chromosome was divided into four equal parts (partitions 1 to 4). The genomic location of each gene prediction determined the relevant partition
allocation.
doi:10.1371/journal.pone.0050609.t007
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Potential Novel Genes
Figure 6 shows the results for finding potential novel genes on
chromosome VIIb using the consensus of predicted sequences
from AUGUSTUS and GlimmerHMM. These consensus se-
quences were derived from aligned grouped sequences based on
overlapping genomic locations of the predicted DNA sequences.
BLASTX was used to determine if any part of the consensus
sequences aligned with existing T. gondii proteins. There were a
total of 594 consensus sequences where each sequence represented
one gene. The highest BLASTX score hit for 568 consensus
sequences was to the T. gondii species. Therefore, 26 out of the 594
consensus sequences had the highest scoring hit to a species other
than Toxoplasma. The highest score hit for 19 of these 26 was to a
phylogenetically similar species called Neospora caninum. When
considering any score, irrespective of how low, 22 of the 26 had a
hit to T gondii. So in summary, four sequences out of 594 did not
have a hit of any kind to a known T. gondii protein. We propose
that these four consensus sequences are potential novel proteins
and are worthy of further investigation. Moreover, these results
indicate that candidate novel proteins can be identified using gene
finder consensus.
There are 678 genes located on the chromosome as per the
number of entries in ToxoDB. We estimate that the number of
genes is between 553 and 653. This estimation is based on the
number of predicted sequences of each gene finder, the number of
partial predictions of the same gene by the same gene finder, and
the number of test genes identified or not identified. Considering
the small number of consensus sequences that did not have a hit to
a known T. gondii protein, we propose that the vast majority of
genes located on chromosome VIIb have been found. These
results are simply an illustration to show that it is feasible to
identify the approximate location of every gene in a genome by
using a pool of ab initio gene finders.
Discussion
There is perception in the scientific community that ab initio
gene finding is diminishing in importance as RNA-seq grows in
importance. It is argued here that there is still a need for research
into finding genes using DNA sequence alone as wet laboratory
experiments currently cannot capture all mRNA. The primary
purpose of this paper was to ascertain if existing ab initio gene
finders had sufficient accuracy to capture all mRNA. Four gene
finders (AUGUSTUS, GeneMark.hmm, GlimmerHMM, and
SNAP) were selected as representatives of high-throughput ab
initio gene finders to evaluate their effectiveness in discovering
proteins encoded in eukaryotic pathogen genomes. The main
findings of the evaluation showed that all four gene finders had low
accuracies of prediction when using the conventional measures of
sensitivity and specificity. Table 12 shows the accuracy of
predictions from previous studies using the same gene finders.
The table also shows for comparison the best accuracy results from
the work conducted for this paper. Realistically the prediction
accuracies can only be compared if the gene finders were trained
on the same genes and the predictions were to the same target
organism. Also in previous studies [9,34,35,55,58,63], although
the same standard equation for sensitivity and specificity was
adopted, the precise method of how the prediction outcomes were
interpreted is not clear. For example, what constitutes a false
negative exon is open to various interpretations. Is it an exon in
the test gene that was not predicted, or is it an exon in the test gene
that was either partly predicted or not at all? Similarly, the specific
criteria used to classify a true positive gene or exon may also be
open to various interpretations. For example, a true positive exon
could either be one that partly overlaps a test exon, or overlaps
above a certain threshold, or overlaps a test exon precisely. The
accuracy values in the table do, however, provide an indication of
the general trend of gene finder performance irrespective of
training data, organism, and evaluation method. The general
Table 8. Comparison of genomic start and end locations of gene predictions with 299 test genes.
Classification** gm aug gl snap all aug:gl:snap aug:gl aug:snap aug:gm gl:snap
Start and End 31 152 93 102 89 112 127 125 116 109
Start 55 47 76 69 70 64 60 65 58 68
End 57 57 85 82 104 92 81 84 82 98
Totally Within 27 4 21 90 75 47 29 21 39 51
Totally Over 116 7 27 27 3 3 4 4 6 7
Overlaps Start 42 6 29 49 7 5 7 6 10 13
Overlaps End 40 5 27 61 7 7 7 6 10 11
Summary (Number of …)
Predictions 580 514 710 895 666 624 594 584 585 730
Test genes identified 299 273 297 283 267 271 273 271 268 281
Test genes not identified 0 26 2 16 32 28 26 28 31 18
Matches with test genes
(includes partial predictions)
368 278 358 480 355 330 315 311 321 357
Partial predictions++ 69 5 61 197 88 59 42 40 53 76
Non-matches$$ 212 236 352 415 311 294 279 273 264 373
Abbreviations:
gm=GeneMark_hmm, aug =AUGUSTUS, gl = GlimmerHMM.
**See Figure 5 for explanation on classifications.
++Number of predicted genes that predict part of an entire gene such that there can be more than one prediction to the same test gene.
$$Number of predictions that did not overlap the test genes in any way.
doi:10.1371/journal.pone.0050609.t008
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trend in previous studies [9,34,35,55,58,63] is that prediction
accuracy increases as per the following gene finder order:
GeneMark_hmm, SNAP, GlimmerHMM, and AUGUSTUS.
The findings presented here support this general trend of accuracy
performance.
The following is a summary of patterns of inaccuracy specific to
the gene finder: SNAP did not predict single exon genes and
tended to make short partial predictions of the same gene – some
of these predictions were duplicates and some partially overlapped;
GlimmerHMM predicted more single exon genes, less exons per
gene, and longer exons than any other gene finder; Gene-
Mark_hmm had a tendency to incorrectly predict the initial or
terminal exon such that the prediction length was longer than the
test gene. No previous study could be found in the literature that
was specific to the evaluated gene finders when used on
apicomplexan genomes. There is one study [56] that used three
gene finders (GeneZilla [34], Twinscan [31], and GlimmerHMM)
to identify genes in the ME49 strain of T. gondii. The study
reported that GlimmerHMM was the least accurate of the three
and the overall false negative rate for all three was about 31–42%
(i.e.proteins that were found experimentally were missed by one or
more of the gene finders) [56]. Several studies [56,64,65,66] have
used transcriptomics and proteomic techniques to evaluate current
genome annotations and improve proteome datasets in key
apicomplexan pathogens.
One of the primary aims of the paper was to identify possible
patterns of prediction inaccuracies for the evaluated gene finders
as a whole irrespective of the target pathogen. From the findings
(see results section for details) the gene finders are inferred to have
the following characteristics when used on any target pathogen:
they predict exons of insufficient accuracy to find novel proteins
without the support of experimental evidence (in agreement with
[8,56,67]); locate the end of a gene precisely more often than the
start of a gene (in agreement with [56]); improve in prediction
accuracy as the number of training genes increase; increase the
number of predictions as the number of training genes increase;
show a tendency not to predict single exon genes or shorter than
average length genes that are located on reverse strands; exhibit a
change in accuracy as the number of nucleotides before and after
the CDS is varied but in a different manner for each gene finder;
perform better when using a model trained on a target rather than
a foreign organism (in agreement with [9]); show greater difficulty
in predicting initial and terminal exons compared to internal exons
(in agreement with [55,56]); have a tendency, when incorrectly
predicting an initial or terminal exon, to predict the initial exon
shorter and the terminal exon longer than the true exon (in
agreement with [58]); show greater difficulty in predicting end
boundary of exon compared to start boundary.(the opposite is
reported in [58]); predict more false positive exons when pathogen
has many introns per gene or has long intergenic regions (in
Table 9. Comparison of test genes not identified by gene
finders.





26 2 16 299
Reverse strand 16 2 12 153
Consecutive groups++ 3 0 2 –
Highest consecutive
number$$
4 0 3 –
Number containing
an N
0 0 0 5
Gene Length
Average 1861 573 1996 5733
Shortest 342 492 342 298
Longest 7332 654 7332 47133
Distance to next test gene
Shortest 52 248 52 52
Longest 69635 7237 69635 106560
Average 11127 2271 10515 11081
Exons
Shortest exon 14 492 14 3
Longest exon 4149 654 1827 9981
Average length 214 573 119 350
Average number per
gene
4 1 5 7
Highest number per
gene
15 1 15 47
Lowest number per
gene
1 1 1 1
Number of single
exons
13 2 9 39
Introns
Shortest intron 51 0 51 51
Longest intron 1074 0 1074 3560
Average length 68 0 43 530
Average number per
gene
3 0 4 6
Highest number per
gene
14 0 14 46
Lowest number per
gene
1 0 1 1
++Number of groups of test genes not found in which the test genes are located
consecutively along the chromosome.
$$The highest number of test genes in a consecutive group.
doi:10.1371/journal.pone.0050609.t009
Table 10. Commonality of test genes not identified by gene finders.
Commonality
Number of genes
not found Single exon gene Reverse strand
% less than
average length**
AUGUSTUS, Glimmer, SNAP 1 1 1 89
AUGUSTUS, SNAP 13 7 9 64
AUGUSTUS, Glimmer 1 1 1 91
**The percentage less than the average length of all the test genes.
doi:10.1371/journal.pone.0050609.t010
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agreement with [55]); and predict more false negative exons when
pathogen has many exons per gene (in agreement with [55]).
The low prediction accuracies suggest that existing ab initio gene
finders have insufficient accuracy to instill confidence that novel
proteins can be found. For example, in an ideal scenario gene
finders would precisely predict the start and end location of each
exon on every validated test gene. In such a scenario, one could
assume that exons from predictions that had no homologous genes
were correct and encoded for novel proteins. Currently, a great
proportion of the exons in the test genes are incorrectly predicted.
Hence there can be no confidence in the predicted exons not
located on test genes. One of the goals of EGASP was to assess
whether gene finders can replace manual annotations. The
conclusion was that no gene finder can deliver perfect predictions
even when all computational methods – ab initio, evidence based
and genome sequence comparison – were employed (including
AUGUSTUS and GeneMark_hmm). Although the evaluated
gene finders had an overall accuracy of more than 80% in
identifying exons correctly, only about 60% of the annotated
protein-coding transcripts were predicted [55]. The current best
solution for finding novel proteins when experimental evidence is
unavailable is to combine the predictions from a pool of ab initio
gene finders as proposed in the literature [55,59,60,61,62].
Despite the overall low accuracy, ab initio gene finders can be
used to locate the approximate location of genes in a genome. We
demonstrated that by using a pool of gene finders the start and end
location of every possible gene can theoretically be identified. We
also suggest that using nucleotide sequences defined by these start
and end locations as separate input sequences to a gene finder will
increase overall prediction accuracy, rather than using an entire
chromosome as input.
We acknowledge that some equally appropriate high-through-
put ab initio gene finders may have been unintentionally missed
during our selection process. At the onset, there were an
overwhelming number of gene finders in the literature to choose
from. In one sense, the post-genomic era has experienced a gold
Table 11. Comparison of genomic start and end locations of exon predictions with exons in test genes (values are percentages).
Classification GeneMark_hmm GeneMark_hmm ES AUGUSTUS GlimmerHMM SNAP
1. Start and End 16 23 57 33 44
2. Start 13 15 7 12 19
3. End 1 3 2 1 2
4. Totally Within 3 3 1 2 3
5. Totally Over 9 9 2 5 6
6. Overlaps Start 11 8 5 7 9
7. Overlaps End 7 6 6 6 8
Number of exons not
classified (no overlap)
40 33 20 34 9
doi:10.1371/journal.pone.0050609.t011
Figure 6. Number of BLASTX hits using DNA consensus sequences from AUGUSTUS and GlimmerHMM predictions. The figure shows
the BLASTX hits when using the consensus of predicted sequences from AUGUSTUS and GlimmerHMM as queries in an attempt to find novel
Toxoplasma gondii proteins. These consensus sequences were derived from aligning predicted DNA sequences based on overlapping genomic
locations (see text for details).
doi:10.1371/journal.pone.0050609.g006
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rush and it is equally difficult for researchers to find the ‘gold’
standard gene finders among so many. Without actually running
the programs it is problematic to determine their efficacy.
Occasionally, program evaluation papers can be found but
become quickly out-dated as new gene finders emerge. Often
the methods behind the programs are hidden from the user, leading
to uncertainties about their confidence, accuracy and information
content [44]. Conversely, the methods are written in the literature
but are too technically and computationally sophisticated for a
biologist to fully understand. It is of course the expertise of a
biologist that in effect converts a program output into scientific
findings worthy of publication. Some gene finders mentioned in
the literature are now potentially lost to the public due to URLs
changing or the program itself being taken offline.
Open source software has been a great gift to research.
Nonetheless it comes with a price. Unlike commercial packages,
there is no financial incentive to provide intensively tested
programs with quality documentation. For the most part, and
especially for specialised programs such as gene finders with a
small user base, there is little or no user documentation, contact
support is rare, and programs are error prone. There are certainly
excellent exceptions to this bleak generalisation of open source
software for gene finders and it has been an objective throughout
the evaluation to find these exceptions.
The quality and quantity of data is indisputably one of the most
important factors that impact the accuracy of ab initio gene finders.
No matter how accurate the gene finder might be, the computer
adage ‘garbage in – garbage out’ holds true. The algorithms of the
programs used in the evaluation require training data and hence
these data-driven programs are only as accurate as the data used to
train them [68]. Ideally, experimentally validated data should be
used in the training data, although even experimental data has the
potential to be incorrect e.g. flawed interpretation of the results or
simply experimental errors.
As shown by the results, gene finders per se are hugely
inaccurate and so finding novel proteins from a purely an ab initio
approach is still a major challenge. It may be unrealistic to expect
gene finders to precisely find real genes in a DNA sequence that is
a mere abstract model of a complex biological system [10]. The
precise number of genes is not known for even the most studied
and characterised complex genome, the human one. The
stumbling block appears to be the split nature of eukaryotic genes
due to introns. It is possible that using only a series of four letters to
model the DNA molecule excludes vital signalling information.
The cellular machinery can apparently recognise and process
signals within the primary DNA sequence and pre-mRNA with
precision [41]. Despite almost 20 years of research there is still no
computational approach that can match the cellular machinery
and consistently predict the exact exon-intron structure of genes
from the DNA sequence alone. Suggesting a completely alterna-
tive computational representation of DNA is not unreasonable in
the light that precise gene finding may simply be impossible with
the current ‘sequence of letters’ representation. It is hypothesised
that the next major breakthrough may be gene decoding in a DNA
model at the atomic level [69,70].
A major limitation of using ab initio gene finders to discover
novel proteins missed by laboratory techniques is instigated by the
biological phenomenon of alternative splicing. Even if the exons
within a novel gene region are precisely predicted, there is
currently no precise computational method to determine which
Table 12. Accuracy of predictions from previous studies (grouped according to target organism).
Gene finder Gene Exon Nucleotide Organism Publication
SN SP SN SP SN SP
SNAP 0.54 0.47 0.83 0.81 0.97 0.95 Arabidopsis thaliana SNAP creator [9]
GlimmerHMM 33% 0.71 0.79 96% Arabidopsis thaliana gl creator [34]
GlimmerHMM 21% 0.36 0.49 91% Aspergillus fumigatus gl creator [34]
SNAP 0.51 0.38 0.79 0.67 0.94 0.87 Drosophila melanogaster SNAP creator [9]
AUGUSTUS 0.51 0.32 0.77 0.68 0.92 0.89 Drosophila melanogaster SNAP creator [9]
AUGUSTUS 0.68 0.38 0.85 0.86 0.98 0.93 Drosophila melanogaster aug creator [35]
AUGUSTUS – – – – 0.92 0.88 Drosophila melanogaster gm creator [63]
SNAP – – – – 0.94 0.86 Drosophila melanogaster gm creator [63]
GeneMark_hmm 0.93 0.88 Drosophila melanogaster gm creator [63]
AUGUSTUS 0.47 0.51 0.71 0.79 – – Drosophila melanogaster Independent [57]
AUGUSTUS 0.48 0.47 0.80 0.81 0.93 0.90 Homo sapiens aug creator [35]
AUGUSTUS 0.24 0.17 0.52 0.63 0.78 0.75 Homo sapiens Independent [55]
AUGUSTUS – – 0.64 0.63 0.81 0.78 Homo sapiens Independent [58]
GeneMark_hmm 0.17 0.08 0.48 0.47 0.76 0.62 Homo sapiens Independent [55]
GlimmerHMM – – 0.69 0.63 0.89 0.79 Homo sapiens Independent [58]
SNAP – – 0.40 0.36 0.72 0.71 Homo sapiens Independent [58]
AUGUSTUS 0.37 0.38 0.57 0.59 0.82 0.79 Toxoplasma gondii This paper
GeneMark _hmm 0.06 0.07 0.15 0.13 0.43 0.37 Toxoplasma gondii This paper
GlimmerHMM 0.20 0.20 0.33 0.35 0.61 0.55 Toxoplasma gondii This paper
SNAP 0.18 0.12 0.44 0.33 0.46 0.35 Toxoplasma gondii This paper
% indicates the percentage of genes and nucleotides predicted exactly. There were no SN or SP values for GlimmerHMM at the gene and nucleotide level.
– No values available.
doi:10.1371/journal.pone.0050609.t012
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exons should be included in the transcript. Alternative splicing can
turn thousands of genes into hundreds of thousands of different
RNA messages. Post-translational modifications can in turn create
millions of different proteins. Millions of proteins can interact in
complex biological networks to form hundreds of millions of
metabolic pathways that ultimately affect the phenotype of the
organism. Therefore to put things into perspective, even if the
challenge of precisely finding exons in genes is realised,
determining the final mature protein is an equally major
challenge. In the evaluation presented in the paper all exons were
included in the translation process. That is, there was no
alternative splicing – only one protein sequence was obtained
per gene prediction and it contained all exons. For future work, an
insight into prevalence and patterns of alternative splicing in
T.gondii genes may be achieved by generating predicted protein
sequences for all possible exon inclusion/exclusion configurations
and then performing homology searches.
The evaluation involved finding novel genes within the DNA
sequence of one genome of a single strain of T.gondii. A genome
sequence of a single strain does not indicate the genetic variability
of a species [71]. The obvious approach to address genetic
variability of a species is to use multiple genome sequences (from
multiple strains of a single species). However, in their paper Mora
and colleagues [71] from research in bacteria state that
‘‘mathematical extrapolation of existing data predicts that no
matter how many strains have been sequenced, each sequence
would contain genes that have not been encountered before’’. The
potential genetic variability may not be as extreme in eukaryotic
pathogens but this extrapolation is an indication that there is still a
long way to go before the pan-genome and the pan-proteome of all
eukaryotic pathogen species is truly captured.
Conclusion
This paper presented an evaluation of high-throughput ab initio
gene finders with the intention of answering the question of
whether existing bioinformatics tools can accurately discover
proteins encoded in eukaryotic pathogen genomes. Whilst not too
undermine the enormous effort in the ab initio gene finders
developed so far, we conclude that the predicted exons are of
insufficient accuracy to be used with confidence in the discovery of
proteins missed by laboratory techniques. That is, their predicted
exon locations are unreliable in the absence of experimental
evidence. Precise exon locations are required for the successful
translation to amino acid sequences. Also, the need for precise
exon boundary delineation is equally important for isolating exons
for alternative transcripts.
The gene finders perform reasonably well in locating the
genomic location of the gene and it is possible to use a pool of gene
finders to identify the approximate location of every gene encoded
in the genome. In other words, candidate novel genes can be
identified using gene finder consensus. Then, a possible exon-
intron structure for these candidate novel genes can be manually
determined from a consensus of their predicted exons. We
hypothesise that knowing at least a crude sequence of a potential
novel protein may help direct the experimental design to discover
the real protein, and its location and function.
The accuracy of gene finding will progressively increase as the
improvements in the quality of sequence data and computational
techniques will inevitably occur. But it is debatable whether gene
finding will ever be an exact science using the current DNA
sequence model. Consequently, in order to exploit the expected
explosion in the number of sequenced genomes, the challenge
remains to develop ab initio gene finders that can find all genes,
precisely identify their exon-intron structures, and handle large
multiple genomes in a timely manner.
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